A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
Terminated · Phase 3 · NCT04161885
Conditions: Acute Myeloid Leukemia (AML), Cancer
At a glance
- Research payments reported, 2025
- $669,846
- U.S. investigators named
- 32
- Sites paid
- 30
- Planned or actual enrollment
- 465
About the trial
- Sponsor
- AbbVie
- Tested
- Venetoclax (drug), Azacitidine (drug), Best Supportive Care (BSC) (other)
- Dates
- Started 2020-02-26; completion 2025-09-23
- Results posted
- Yes
The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Overall Survival (OS) in Acute Myeloid Leukemia (AML) participants compared to Best Supportive Care (BSC) when given as maintenance therapy following allogeneic stem cell transplantation (SCT). This study will have 2 parts: Part 1 (Dose Confirmation), which may include participants who are greater than or equal to 18 years old; Part 2 (Randomization) which may include participants who are greater than or equal to 12 years old. During Part 1, recommended Phase 3 dose of venetoclax in combination with azacitidine will be determined and during Part 2, the efficacy and safety …
From ClinicalTrials.gov, last updated 2026-06-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $669,846 in research payments for this study in 2025 (256 payments).
Products named: Venclexta
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Sharad Khurana, MD, MSC Hematology & Oncology · Tucson, AZ
- Vinod Pullarkat, M.D. Hematology · Duarte, CA
- Jonathan A. Gutman, MD Medical Oncology · Aurora, CO
- Hemant S. Murthy, M.D. Hematology & Oncology · Jacksonville, FL
- Rushang D. Patel, M.D, PH.D. Medical Oncology · Orlando, FL
- Hyung C. Suh, M.D. Medical Oncology · Tampa, FL
- Zachariah Defilipp, M.D. Hematology & Oncology · Atlanta, GA
- Katarzyna J. Jamieson, MD Hematology & Oncology · Iowa City, IA
- Sonali S. Chaudhury, MD Pediatric Hematology & Oncology · Chicago, IL
- Patrick A. Hagen, M.D., M.P.H Hematology & Oncology · Maywood, IL
- Wendy Stock Hematology & Oncology · Chicago, IL
- Jean Yared, M.D. Hematology & Oncology · Baltimore, MD
- Joseph P. Uberti, MD PHD Hematology & Oncology · Detroit, MI
- Mark B. Juckett, MD Hematology · Minneapolis, MN
- Mithun V. Shah, MD, PHD Hematology · Rochester, MN
- Jonathan E. Lambird, M.D. Hematology & Oncology · Winston Salem, NC
- Juan C. Varela, M.D., PHD Hematology · Winston Salem, NC
- Michele L. Donato, MD Medical Oncology · Hackensack, NJ
- Esperanza Papadopoulos, MD Hematology · New York, NY
- Bryan C. Hambley, M.D. Hematology · Cincinnati, OH
- Benjamin K. Tomlinson Hematology & Oncology · Cleveland, OH
- Jennifer L. Holter-chakrabarty, MD Hematology & Oncology · Oklahoma City, OK
- Rachel J. Cook, M.D. Hematology · Portland, OR
- Jingzhou Hou Hematology & Oncology · Pittsburgh, PA
- Shin Mineishi, MD Medical Oncology · Hershey, PA
- Keith W. Pratz, M.D. Hematology & Oncology · Philadelphia, PA
- Alix Seif, M.D., MPH Pediatric Hematology & Oncology · Philadelphia, PA
- Jeremy M. Pantin, M.D. Hematology & Oncology · Nashville, TN
- Vikas Bhushan, M.D. Hematology & Oncology · Dallas, TX
- Luis Pineiro, MD Hematology & Oncology · Dallas, TX
- Bart L. Scott Medical Oncology · Seattle, WA
- Aric C. Hall, M.D. Hematology & Oncology · Madison, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Fred Hutchinson Cancer Center $85,050
- The Board of Regents of the University of Wisconsin System $63,854
- Adventhealth Orlando, FL $51,650
- University of Maryland Baltimore $40,612
- Ann & Robert H Lurie Childrens Hospital of Chicago, IL $40,465
- University of Cincinnati $31,456
- Wake Forest University Health Sciences $30,700
- Regents of the University of Colorado $30,592
- Children's Hospital of Philadelphia, PA $27,410
- Texas Oncology PA $26,169
- University of Minnesota Regents $25,480
- University of North Carolina at Chapel Hill $25,302
- University of Arizona $23,897
- City of Hope National Medical Ctr $23,322
- Board of Regents of the University of Oklahoma Health Sciences Center $17,977
- Jfk University Medical Center, NJ $15,843
- Rainbow Babies and Childrens Hospital, OH $13,887
- Ohsu Hospital and Clinics, OR $13,022
- Hospital of Univ of Pennsylvania, PA $12,175
- Karmanos Cancer Center, MI $11,880
- Hackensack University Medical Center, NJ $11,874
- Pennsylvania State University $10,026
- Mayo Clinic Jacksonville $7,500
- University of Chicago $7,250
- Dana-Farberpartners Cancercare Inc $7,225
- $4,350
- Loyola Stritch School of Medicine Division of Dermatology $3,246
- Memorial Sloan Kettering Cancer Center $3,226
- University of Pittsburgh Cancer Institute Cancer Services $2,717
- Sarah Cannon Research Institute LLC $1,300
- Mayo Clinic Rochester $390
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.